nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Hypochloraemia—Epirubicin—liver cancer	0.0388	0.0388	CcSEcCtD
Metolazone—Hypochloraemia—Doxorubicin—liver cancer	0.0359	0.0359	CcSEcCtD
Metolazone—Hypophosphataemia—Sorafenib—liver cancer	0.0279	0.0279	CcSEcCtD
Metolazone—Oropharyngeal discomfort—Sorafenib—liver cancer	0.0223	0.0223	CcSEcCtD
Metolazone—Skin necrosis—Epirubicin—liver cancer	0.0172	0.0172	CcSEcCtD
Metolazone—Skin necrosis—Doxorubicin—liver cancer	0.0159	0.0159	CcSEcCtD
Metolazone—Skin exfoliation—Sorafenib—liver cancer	0.0155	0.0155	CcSEcCtD
Metolazone—Neuropathy—Sorafenib—liver cancer	0.0152	0.0152	CcSEcCtD
Metolazone—Hyponatraemia—Sorafenib—liver cancer	0.0118	0.0118	CcSEcCtD
Metolazone—Venous thrombosis—Epirubicin—liver cancer	0.0111	0.0111	CcSEcCtD
Metolazone—Dry skin—Sorafenib—liver cancer	0.0108	0.0108	CcSEcCtD
Metolazone—Hypokalaemia—Sorafenib—liver cancer	0.0107	0.0107	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.0106	0.0106	CcSEcCtD
Metolazone—Hypophosphataemia—Epirubicin—liver cancer	0.0103	0.0103	CcSEcCtD
Metolazone—Venous thrombosis—Doxorubicin—liver cancer	0.0103	0.0103	CcSEcCtD
Metolazone—Pancreatitis—Sorafenib—liver cancer	0.00998	0.00998	CcSEcCtD
Metolazone—Abdominal discomfort—Sorafenib—liver cancer	0.00976	0.00976	CcSEcCtD
Metolazone—Hypophosphataemia—Doxorubicin—liver cancer	0.00955	0.00955	CcSEcCtD
Metolazone—Hypomagnesaemia—Epirubicin—liver cancer	0.00944	0.00944	CcSEcCtD
Metolazone—Erectile dysfunction—Sorafenib—liver cancer	0.00938	0.00938	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.009	0.009	CcSEcCtD
Metolazone—Neuropathy peripheral—Sorafenib—liver cancer	0.0089	0.0089	CcSEcCtD
Metolazone—Hypomagnesaemia—Doxorubicin—liver cancer	0.00874	0.00874	CcSEcCtD
Metolazone—Hypercalcaemia—Epirubicin—liver cancer	0.00863	0.00863	CcSEcCtD
Metolazone—Epistaxis—Sorafenib—liver cancer	0.00856	0.00856	CcSEcCtD
Metolazone—Hypercalcaemia—Doxorubicin—liver cancer	0.00799	0.00799	CcSEcCtD
Metolazone—Erythema multiforme—Sorafenib—liver cancer	0.00771	0.00771	CcSEcCtD
Metolazone—Tinnitus—Sorafenib—liver cancer	0.0076	0.0076	CcSEcCtD
Metolazone—Glycosuria—Epirubicin—liver cancer	0.0074	0.0074	CcSEcCtD
Metolazone—Petechiae—Epirubicin—liver cancer	0.00729	0.00729	CcSEcCtD
Metolazone—Dysgeusia—Sorafenib—liver cancer	0.00695	0.00695	CcSEcCtD
Metolazone—Glycosuria—Doxorubicin—liver cancer	0.00685	0.00685	CcSEcCtD
Metolazone—Jaundice cholestatic—Epirubicin—liver cancer	0.00683	0.00683	CcSEcCtD
Metolazone—Muscle spasms—Sorafenib—liver cancer	0.00682	0.00682	CcSEcCtD
Metolazone—Petechiae—Doxorubicin—liver cancer	0.00675	0.00675	CcSEcCtD
Metolazone—Anaemia—Sorafenib—liver cancer	0.00656	0.00656	CcSEcCtD
Metolazone—Nocturia—Epirubicin—liver cancer	0.00647	0.00647	CcSEcCtD
Metolazone—Hyperuricaemia—Epirubicin—liver cancer	0.00647	0.00647	CcSEcCtD
Metolazone—Syncope—Sorafenib—liver cancer	0.00636	0.00636	CcSEcCtD
Metolazone—Leukopenia—Sorafenib—liver cancer	0.00635	0.00635	CcSEcCtD
Metolazone—Jaundice cholestatic—Doxorubicin—liver cancer	0.00632	0.00632	CcSEcCtD
Metolazone—Loss of consciousness—Sorafenib—liver cancer	0.00624	0.00624	CcSEcCtD
Metolazone—Cough—Sorafenib—liver cancer	0.00619	0.00619	CcSEcCtD
Metolazone—Hypertension—Sorafenib—liver cancer	0.00613	0.00613	CcSEcCtD
Metolazone—Blood uric acid increased—Epirubicin—liver cancer	0.00611	0.00611	CcSEcCtD
Metolazone—Arthralgia—Sorafenib—liver cancer	0.00604	0.00604	CcSEcCtD
Metolazone—Hyperuricaemia—Doxorubicin—liver cancer	0.00598	0.00598	CcSEcCtD
Metolazone—Nocturia—Doxorubicin—liver cancer	0.00598	0.00598	CcSEcCtD
Metolazone—Dry mouth—Sorafenib—liver cancer	0.00591	0.00591	CcSEcCtD
Metolazone—Skin exfoliation—Epirubicin—liver cancer	0.00573	0.00573	CcSEcCtD
Metolazone—Shock—Sorafenib—liver cancer	0.0057	0.0057	CcSEcCtD
Metolazone—Thrombocytopenia—Sorafenib—liver cancer	0.00567	0.00567	CcSEcCtD
Metolazone—Blood urea increased—Epirubicin—liver cancer	0.00566	0.00566	CcSEcCtD
Metolazone—Blood uric acid increased—Doxorubicin—liver cancer	0.00565	0.00565	CcSEcCtD
Metolazone—Neuropathy—Epirubicin—liver cancer	0.00563	0.00563	CcSEcCtD
Metolazone—Anorexia—Sorafenib—liver cancer	0.00552	0.00552	CcSEcCtD
Metolazone—Skin exfoliation—Doxorubicin—liver cancer	0.0053	0.0053	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00528	0.00528	CcSEcCtD
Metolazone—Blood urea increased—Doxorubicin—liver cancer	0.00524	0.00524	CcSEcCtD
Metolazone—Neuropathy—Doxorubicin—liver cancer	0.00521	0.00521	CcSEcCtD
Metolazone—Dyspepsia—Sorafenib—liver cancer	0.0051	0.0051	CcSEcCtD
Metolazone—Decreased appetite—Sorafenib—liver cancer	0.00503	0.00503	CcSEcCtD
Metolazone—Fatigue—Sorafenib—liver cancer	0.00499	0.00499	CcSEcCtD
Metolazone—Photosensitivity—Epirubicin—liver cancer	0.00496	0.00496	CcSEcCtD
Metolazone—Constipation—Sorafenib—liver cancer	0.00495	0.00495	CcSEcCtD
Metolazone—Pain—Sorafenib—liver cancer	0.00495	0.00495	CcSEcCtD
Metolazone—Vascular purpura—Epirubicin—liver cancer	0.00487	0.00487	CcSEcCtD
Metolazone—Gastrointestinal pain—Sorafenib—liver cancer	0.00474	0.00474	CcSEcCtD
Metolazone—Urticaria—Sorafenib—liver cancer	0.0046	0.0046	CcSEcCtD
Metolazone—Photosensitivity—Doxorubicin—liver cancer	0.00459	0.00459	CcSEcCtD
Metolazone—Abdominal pain—Sorafenib—liver cancer	0.00458	0.00458	CcSEcCtD
Metolazone—Purpura—Epirubicin—liver cancer	0.00452	0.00452	CcSEcCtD
Metolazone—Vascular purpura—Doxorubicin—liver cancer	0.0045	0.0045	CcSEcCtD
Metolazone—Lethargy—Epirubicin—liver cancer	0.00444	0.00444	CcSEcCtD
Metolazone—Hyponatraemia—Epirubicin—liver cancer	0.00437	0.00437	CcSEcCtD
Metolazone—Hypersensitivity—Sorafenib—liver cancer	0.00427	0.00427	CcSEcCtD
Metolazone—Purpura—Doxorubicin—liver cancer	0.00418	0.00418	CcSEcCtD
Metolazone—Asthenia—Sorafenib—liver cancer	0.00415	0.00415	CcSEcCtD
Metolazone—Lethargy—Doxorubicin—liver cancer	0.00411	0.00411	CcSEcCtD
Metolazone—Pruritus—Sorafenib—liver cancer	0.0041	0.0041	CcSEcCtD
Metolazone—Hyponatraemia—Doxorubicin—liver cancer	0.00405	0.00405	CcSEcCtD
Metolazone—Dry skin—Epirubicin—liver cancer	0.00399	0.00399	CcSEcCtD
Metolazone—Orthostatic hypotension—Epirubicin—liver cancer	0.00398	0.00398	CcSEcCtD
Metolazone—Hypokalaemia—Epirubicin—liver cancer	0.00396	0.00396	CcSEcCtD
Metolazone—Diarrhoea—Sorafenib—liver cancer	0.00396	0.00396	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00392	0.00392	CcSEcCtD
Metolazone—Dizziness—Sorafenib—liver cancer	0.00383	0.00383	CcSEcCtD
Metolazone—Abdominal distension—Epirubicin—liver cancer	0.00379	0.00379	CcSEcCtD
Metolazone—Dry skin—Doxorubicin—liver cancer	0.00369	0.00369	CcSEcCtD
Metolazone—Pancreatitis—Epirubicin—liver cancer	0.00369	0.00369	CcSEcCtD
Metolazone—Vomiting—Sorafenib—liver cancer	0.00368	0.00368	CcSEcCtD
Metolazone—Orthostatic hypotension—Doxorubicin—liver cancer	0.00368	0.00368	CcSEcCtD
Metolazone—Hypokalaemia—Doxorubicin—liver cancer	0.00367	0.00367	CcSEcCtD
Metolazone—Rash—Sorafenib—liver cancer	0.00365	0.00365	CcSEcCtD
Metolazone—Dermatitis—Sorafenib—liver cancer	0.00365	0.00365	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00363	0.00363	CcSEcCtD
Metolazone—Headache—Sorafenib—liver cancer	0.00363	0.00363	CcSEcCtD
Metolazone—Abdominal distension—Doxorubicin—liver cancer	0.00351	0.00351	CcSEcCtD
Metolazone—Nausea—Sorafenib—liver cancer	0.00344	0.00344	CcSEcCtD
Metolazone—Photosensitivity reaction—Epirubicin—liver cancer	0.00344	0.00344	CcSEcCtD
Metolazone—Pancreatitis—Doxorubicin—liver cancer	0.00341	0.00341	CcSEcCtD
Metolazone—Hyperglycaemia—Epirubicin—liver cancer	0.00339	0.00339	CcSEcCtD
Metolazone—Drowsiness—Epirubicin—liver cancer	0.00336	0.00336	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00333	0.00333	CcSEcCtD
Metolazone—Neuropathy peripheral—Epirubicin—liver cancer	0.00329	0.00329	CcSEcCtD
Metolazone—Photosensitivity reaction—Doxorubicin—liver cancer	0.00318	0.00318	CcSEcCtD
Metolazone—Epistaxis—Epirubicin—liver cancer	0.00316	0.00316	CcSEcCtD
Metolazone—Hyperglycaemia—Doxorubicin—liver cancer	0.00314	0.00314	CcSEcCtD
Metolazone—Agranulocytosis—Epirubicin—liver cancer	0.00313	0.00313	CcSEcCtD
Metolazone—Drowsiness—Doxorubicin—liver cancer	0.0031	0.0031	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00308	0.00308	CcSEcCtD
Metolazone—Neuropathy peripheral—Doxorubicin—liver cancer	0.00304	0.00304	CcSEcCtD
Metolazone—Hepatitis—Epirubicin—liver cancer	0.00301	0.00301	CcSEcCtD
Metolazone—Epistaxis—Doxorubicin—liver cancer	0.00293	0.00293	CcSEcCtD
Metolazone—Agranulocytosis—Doxorubicin—liver cancer	0.0029	0.0029	CcSEcCtD
Metolazone—Erythema multiforme—Epirubicin—liver cancer	0.00285	0.00285	CcSEcCtD
Metolazone—Tinnitus—Epirubicin—liver cancer	0.00281	0.00281	CcSEcCtD
Metolazone—Hepatitis—Doxorubicin—liver cancer	0.00279	0.00279	CcSEcCtD
Metolazone—Chills—Epirubicin—liver cancer	0.0027	0.0027	CcSEcCtD
Metolazone—Erythema multiforme—Doxorubicin—liver cancer	0.00264	0.00264	CcSEcCtD
Metolazone—Tinnitus—Doxorubicin—liver cancer	0.0026	0.0026	CcSEcCtD
Metolazone—Flatulence—Epirubicin—liver cancer	0.00258	0.00258	CcSEcCtD
Metolazone—Tension—Epirubicin—liver cancer	0.00257	0.00257	CcSEcCtD
Metolazone—Dysgeusia—Epirubicin—liver cancer	0.00257	0.00257	CcSEcCtD
Metolazone—Nervousness—Epirubicin—liver cancer	0.00255	0.00255	CcSEcCtD
Metolazone—Back pain—Epirubicin—liver cancer	0.00254	0.00254	CcSEcCtD
Metolazone—Muscle spasms—Epirubicin—liver cancer	0.00252	0.00252	CcSEcCtD
Metolazone—Chills—Doxorubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Metolazone—Vision blurred—Epirubicin—liver cancer	0.00247	0.00247	CcSEcCtD
Metolazone—Ill-defined disorder—Epirubicin—liver cancer	0.00243	0.00243	CcSEcCtD
Metolazone—Anaemia—Epirubicin—liver cancer	0.00242	0.00242	CcSEcCtD
Metolazone—Agitation—Epirubicin—liver cancer	0.00241	0.00241	CcSEcCtD
Metolazone—Flatulence—Doxorubicin—liver cancer	0.00239	0.00239	CcSEcCtD
Metolazone—Tension—Doxorubicin—liver cancer	0.00238	0.00238	CcSEcCtD
Metolazone—Dysgeusia—Doxorubicin—liver cancer	0.00238	0.00238	CcSEcCtD
Metolazone—Malaise—Epirubicin—liver cancer	0.00236	0.00236	CcSEcCtD
Metolazone—Nervousness—Doxorubicin—liver cancer	0.00236	0.00236	CcSEcCtD
Metolazone—Vertigo—Epirubicin—liver cancer	0.00236	0.00236	CcSEcCtD
Metolazone—Syncope—Epirubicin—liver cancer	0.00235	0.00235	CcSEcCtD
Metolazone—Leukopenia—Epirubicin—liver cancer	0.00235	0.00235	CcSEcCtD
Metolazone—Back pain—Doxorubicin—liver cancer	0.00235	0.00235	CcSEcCtD
Metolazone—Muscle spasms—Doxorubicin—liver cancer	0.00233	0.00233	CcSEcCtD
Metolazone—Palpitations—Epirubicin—liver cancer	0.00232	0.00232	CcSEcCtD
Metolazone—Loss of consciousness—Epirubicin—liver cancer	0.0023	0.0023	CcSEcCtD
Metolazone—Cough—Epirubicin—liver cancer	0.00229	0.00229	CcSEcCtD
Metolazone—Vision blurred—Doxorubicin—liver cancer	0.00229	0.00229	CcSEcCtD
Metolazone—Hypertension—Epirubicin—liver cancer	0.00226	0.00226	CcSEcCtD
Metolazone—Ill-defined disorder—Doxorubicin—liver cancer	0.00225	0.00225	CcSEcCtD
Metolazone—Anaemia—Doxorubicin—liver cancer	0.00224	0.00224	CcSEcCtD
Metolazone—Arthralgia—Epirubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Metolazone—Chest pain—Epirubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Metolazone—Agitation—Doxorubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Metolazone—Anxiety—Epirubicin—liver cancer	0.00222	0.00222	CcSEcCtD
Metolazone—Discomfort—Epirubicin—liver cancer	0.00221	0.00221	CcSEcCtD
Metolazone—Malaise—Doxorubicin—liver cancer	0.00219	0.00219	CcSEcCtD
Metolazone—Dry mouth—Epirubicin—liver cancer	0.00218	0.00218	CcSEcCtD
Metolazone—Vertigo—Doxorubicin—liver cancer	0.00218	0.00218	CcSEcCtD
Metolazone—Syncope—Doxorubicin—liver cancer	0.00218	0.00218	CcSEcCtD
Metolazone—Leukopenia—Doxorubicin—liver cancer	0.00217	0.00217	CcSEcCtD
Metolazone—Palpitations—Doxorubicin—liver cancer	0.00214	0.00214	CcSEcCtD
Metolazone—Loss of consciousness—Doxorubicin—liver cancer	0.00213	0.00213	CcSEcCtD
Metolazone—Cough—Doxorubicin—liver cancer	0.00212	0.00212	CcSEcCtD
Metolazone—Shock—Epirubicin—liver cancer	0.00211	0.00211	CcSEcCtD
Metolazone—Thrombocytopenia—Epirubicin—liver cancer	0.0021	0.0021	CcSEcCtD
Metolazone—Hypertension—Doxorubicin—liver cancer	0.00209	0.00209	CcSEcCtD
Metolazone—Arthralgia—Doxorubicin—liver cancer	0.00207	0.00207	CcSEcCtD
Metolazone—Chest pain—Doxorubicin—liver cancer	0.00207	0.00207	CcSEcCtD
Metolazone—Anxiety—Doxorubicin—liver cancer	0.00206	0.00206	CcSEcCtD
Metolazone—Discomfort—Doxorubicin—liver cancer	0.00204	0.00204	CcSEcCtD
Metolazone—Anorexia—Epirubicin—liver cancer	0.00204	0.00204	CcSEcCtD
Metolazone—Dry mouth—Doxorubicin—liver cancer	0.00202	0.00202	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00195	0.00195	CcSEcCtD
Metolazone—Shock—Doxorubicin—liver cancer	0.00195	0.00195	CcSEcCtD
Metolazone—Thrombocytopenia—Doxorubicin—liver cancer	0.00194	0.00194	CcSEcCtD
Metolazone—Insomnia—Epirubicin—liver cancer	0.00194	0.00194	CcSEcCtD
Metolazone—Paraesthesia—Epirubicin—liver cancer	0.00192	0.00192	CcSEcCtD
Metolazone—Somnolence—Epirubicin—liver cancer	0.0019	0.0019	CcSEcCtD
Metolazone—Anorexia—Doxorubicin—liver cancer	0.00189	0.00189	CcSEcCtD
Metolazone—Dyspepsia—Epirubicin—liver cancer	0.00188	0.00188	CcSEcCtD
Metolazone—Decreased appetite—Epirubicin—liver cancer	0.00186	0.00186	CcSEcCtD
Metolazone—Fatigue—Epirubicin—liver cancer	0.00185	0.00185	CcSEcCtD
Metolazone—Pain—Epirubicin—liver cancer	0.00183	0.00183	CcSEcCtD
Metolazone—Constipation—Epirubicin—liver cancer	0.00183	0.00183	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.0018	0.0018	CcSEcCtD
Metolazone—Insomnia—Doxorubicin—liver cancer	0.00179	0.00179	CcSEcCtD
Metolazone—Paraesthesia—Doxorubicin—liver cancer	0.00178	0.00178	CcSEcCtD
Metolazone—Feeling abnormal—Epirubicin—liver cancer	0.00176	0.00176	CcSEcCtD
Metolazone—Somnolence—Doxorubicin—liver cancer	0.00176	0.00176	CcSEcCtD
Metolazone—Gastrointestinal pain—Epirubicin—liver cancer	0.00175	0.00175	CcSEcCtD
Metolazone—Dyspepsia—Doxorubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Metolazone—Decreased appetite—Doxorubicin—liver cancer	0.00172	0.00172	CcSEcCtD
Metolazone—Fatigue—Doxorubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Metolazone—Urticaria—Epirubicin—liver cancer	0.0017	0.0017	CcSEcCtD
Metolazone—Pain—Doxorubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Metolazone—Constipation—Doxorubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Metolazone—Abdominal pain—Epirubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Metolazone—Feeling abnormal—Doxorubicin—liver cancer	0.00163	0.00163	CcSEcCtD
Metolazone—Gastrointestinal pain—Doxorubicin—liver cancer	0.00162	0.00162	CcSEcCtD
Metolazone—Hypersensitivity—Epirubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Metolazone—Urticaria—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Metolazone—Abdominal pain—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Metolazone—Asthenia—Epirubicin—liver cancer	0.00154	0.00154	CcSEcCtD
Metolazone—Pruritus—Epirubicin—liver cancer	0.00151	0.00151	CcSEcCtD
Metolazone—Diarrhoea—Epirubicin—liver cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Hypersensitivity—Doxorubicin—liver cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Asthenia—Doxorubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Metolazone—Dizziness—Epirubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Metolazone—Pruritus—Doxorubicin—liver cancer	0.0014	0.0014	CcSEcCtD
Metolazone—Vomiting—Epirubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Metolazone—Diarrhoea—Doxorubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Rash—Epirubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Dermatitis—Epirubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Headache—Epirubicin—liver cancer	0.00134	0.00134	CcSEcCtD
Metolazone—Dizziness—Doxorubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Metolazone—Nausea—Epirubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Vomiting—Doxorubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Metolazone—Rash—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Dermatitis—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Headache—Doxorubicin—liver cancer	0.00124	0.00124	CcSEcCtD
Metolazone—Nausea—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
